Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 14/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407835 | 1.00 | SLC5A2 (0.56) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 | |
| SCHEMBL3407836 | 1.00 | SLC5A2 (0.56) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 | |
| SCHEMBL3406446 | 0.92 | SLC5A2 (0.55) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 | |
| SCHEMBL3406449 | 0.92 | SLC5A2 (0.55) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 | |
| SCHEMBL4423504 | 0.85 | SLC5A2 (0.75) | SLC5A2SLC5A1 | |
| SCHEMBL3414167 | 0.85 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL3414169 | 0.85 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL3411735 | 0.83 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL3407831 | 0.83 | SLC5A2 (0.57) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 | |
| SCHEMBL3408444 | 0.83 | SLC5A2 (0.57) | SLC5A2SLC5A1CHRM5CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816331-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | PATEL MONA | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | GYS2, GPR119, UGGT1 | SLC5A2 10/4885SLC5A1 9/4885CHRM5 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.